Federal Circuit Instructs PTO to Allow Companies to Amend IPR-Challenged Patents

Drug Industry Daily
The Federal Circuit eased the ability for patent holders to amend their claims when challenged under inter partes review — a hurdle that pharmaceutical industry trade groups had previously described as unfair, ambiguous and impractical.

To View This Article:


Subscribe To Drug Industry Daily